TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22854323

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 20071999

Group type: EXPERIMENTAL
Intervention: Vicriviroc 5 mg once daily
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vicriviroc 10 mg once daily
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vicriviroc 15 mg once daily
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vicriviroc (all doses)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17888074

Group type: EXPERIMENTAL
Intervention: AED withdrawal
Number of subjects: 160

Group type: COMPARATOR
Intervention: Nonwithdrawal (control)
Number of subjects: 160
Study: 19497249

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15892782

Group type: EXPERIMENTAL
Intervention: Learning exemplars characterized by common function
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Learning exemplars characterized by common appearance
Number of subjects: 98
Study: 12366485

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 210

Group type: COMPARATOR
Intervention: False acupuncture (control)
Number of subjects: 210
Study: 9692101

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation (21 min-1) during FOB and continued for 120 min after FOB in group 2.
Number of subjects: 34

Group type: COMPARATOR
Intervention: No oxygen supplementation after FOB in group 1.
Number of subjects: 34
Study: 7823546

Group type: EXPERIMENTAL
Intervention: 4-hour hydration treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4-hour dehydration treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: 4-hour placebo (control) treatment
Number of subjects: 12
Study: 3350160

Group type: EXPERIMENTAL
Intervention: Intravaginal culture (IVC)
Number of subjects: 160
Study: 11403534

Group type: COMPARATOR
Intervention: Proton pump inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acid suppression
Number of subjects: 0
Study: 31182528

Group type: COMPARATOR
Intervention: GSK3036656 single doses of 5 mg (fed and fasted), 15 mg, and 25 mg; placebo as control
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK3036656 repeat doses of 5 mg and 15 mg; placebo as control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK3036656 (both single and multiple doses)
Number of subjects: 0
Study: 29077783

Group type: EXPERIMENTAL
Intervention: Mental fatigue intervention (performing a stop-signal task for 90 minutes)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control intervention (watching a video for 90 minutes)
Number of subjects: 32
Study: 27424014

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin (Group A)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Topical diltiazem (Group B)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Surgical treatment (Group C)
Number of subjects: 190
Study: 24399268

Group type: EXPERIMENTAL
Intervention: Tailored text messages
Number of subjects: 2030

Group type: COMPARATOR
Intervention: Untailored text messages
Number of subjects: 2030

Group type: EXPERIMENTAL
Intervention: Tailored text messages (restricted analysis)
Number of subjects: 2030

Group type: COMPARATOR
Intervention: Untailored text messages (restricted analysis)
Number of subjects: 2030
Study: 23359967

Group type: EXPERIMENTAL
Intervention: ATRA combined with Compound Huangdai Tablet
Number of subjects: 83

Group type: COMPARATOR
Intervention: ATRA combined with MTX + 6MP
Number of subjects: 83
Study: 20028919

Group type: EXPERIMENTAL
Intervention: Interferon (intermediate- versus low-dose)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Baseline tumor blood flow
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tumor blood flow and mean transit time (MTT) at follow-up
Number of subjects: 37
Study: 17922014

Group type: EXPERIMENTAL
Intervention: HMMR locus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Network modeling strategy
Number of subjects: 0
Study: 16198089

Group type: EXPERIMENTAL
Intervention: Speech discrimination training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 17
Study: 11953279

Group type: EXPERIMENTAL
Intervention: Inhalative mucolytic drug mercapto‐ethane sulfonate (Mesna)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10404292

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 8669222

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg/kg (group A)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.17 mg/kg (group B)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.19 mg/kg (group C)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 3
Study: 2161615

Group type: EXPERIMENTAL
Intervention: 6% maltodextrin (6% M)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 6% glucose-fructose mix (6% GF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 8% glucose-fructose mix (8% GF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10% glucose-fructose mix (10% GF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water placebo (W)
Number of subjects: 8
Study: 271589

Group type: EXPERIMENTAL
Intervention: Roll technique
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bass technique
Number of subjects: 28
Study: 31511080

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with ambrisentan 10 mg plus tadalafil 40 mg
Number of subjects: 500

Group type: COMPARATOR
Intervention: Pooled monotherapy (ambrisentan 10 mg plus placebo or tadalafil 40 mg plus placebo)
Number of subjects: 500
Study: 28940368

Group type: EXPERIMENTAL
Intervention: Intervention group (cerebral oximetry monitoring with algorithm activation if saturation < 75%)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group (cerebral oximetry monitor screen blinded)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Patients with baseline regional cerebral oxygen saturation ≤ 50%
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Patients with baseline regional cerebral oxygen saturation > 50%
Number of subjects: 249
Study: 26179177

Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSAs) for 6 months
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 55
Study: 24633859

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 217

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 217
Study: 22539172

Group type: EXPERIMENTAL
Intervention: Structured group education programme for six hours delivered in the community by two trained healthcare professional educators
Number of subjects: 731

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 731
Study: 18759737

Group type: EXPERIMENTAL
Intervention: Tertiary individual prevention (TIP) - 3 weeks inpatient treatment including intensive health care instruction and psychological counseling, followed by outpatient treatment by the local dermatologist.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Secondary individual prevention (SIP) - combined outpatient dermatologic and health-educational intervention seminars.
Number of subjects: 1000
Study: 17121868

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airways Pressure (CPAP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Oral Appliance
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conservative Measures (sleep hygiene)
Number of subjects: 101
Study: 15888698

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 695

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 695
Study: 15060873

Group type: EXPERIMENTAL
Intervention: Ketodiet (0.3 g/kg/d protein plus tablets of KAs)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (0.6 g/kg/d protein plus placebo)
Number of subjects: 34
Study: 11552770

Group type: EXPERIMENTAL
Intervention: Reboxetine add on to haloperidol 5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo add on to haloperidol 5 mg
Number of subjects: 30
Study: 9760358

Group type: EXPERIMENTAL
Intervention: DentinBloc cavity liner
Number of subjects: 16

Group type: COMPARATOR
Intervention: Copalite cavity liner
Number of subjects: 16
Study: 7936817

Group type: EXPERIMENTAL
Intervention: Breath‐by‐breath alternations in fractional inspired oxygen concentration (0.21 and 0.16)
Number of subjects: 8
Study: 3125882

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin daily
Number of subjects: 5139

Group type: COMPARATOR
Intervention: Control group (not given a placebo)
Number of subjects: 5139
Study: 29697508

Group type: EXPERIMENTAL
Intervention: In-line filtration
Number of subjects: 268

Group type: COMPARATOR
Intervention: No-filter (standard care)
Number of subjects: 268
Study: 28242866

Group type: EXPERIMENTAL
Intervention: Mitiglinide (10 mg) and Voglibose (0.2 mg) (M+V) 3 times daily
Number of subjects: 5

Group type: COMPARATOR
Intervention: Dipeptidyl Peptidase-4 Inhibitor (Linagliptin 5 mg) (L) once daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both groups (M+V and L)
Number of subjects: 5
Study: 24203489

Group type: EXPERIMENTAL
Intervention: Standardized mindfulness
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Spiritualized mindfulness
Number of subjects: 107

Group type: COMPARATOR
Intervention: Simple relaxation
Number of subjects: 107
Study: 23292563

Group type: EXPERIMENTAL
Intervention: Surgeon viewed 3D reconstruction before and during surgery
Number of subjects: 112

Group type: COMPARATOR
Intervention: Surgeon viewed 3D reconstruction after surgery
Number of subjects: 112
Study: 21553974

Group type: EXPERIMENTAL
Intervention: Question-behavior effect condition (completed questionnaire about health checks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Question-behavior effect condition (completed questionnaire about influenza vaccination)
Number of subjects: 0
Study: 18974657

Group type: EXPERIMENTAL
Intervention: Antibiotic ointment (AO) prophylaxis
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Catheter antimicrobial locking (AL) with heparin + gentamicin (5.2 mg/ml)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both AO and AL prophylaxis
Number of subjects: 116
Study: 16957997

Group type: EXPERIMENTAL
Intervention: Surgical techniques or methods for hepatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical techniques or methods for pancreatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicenter studies on hepatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promotion of multicenter studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adequate RCTs observing the Consolidated Standards of Reporting Trials statements
Number of subjects: 0
Study: 12915429

Group type: EXPERIMENTAL
Intervention: Standard-dose guggulipid (1000 mg)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: High-dose guggulipid (2000 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Guggulipid (both doses)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Guggulipid
Number of subjects: 103
Study: 10834782

Group type: EXPERIMENTAL
Intervention: Ziconotide 0.7 microg/h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ziconotide 7.0 microg/h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10163305

Group type: EXPERIMENTAL
Intervention: Exposure to chemical hazards
Number of subjects: 1841

Group type: EXPERIMENTAL
Intervention: Concern about exposure to chemical hazards
Number of subjects: 1841
Study: 1539474

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopentone 4.5 mg.kg‐1
Number of subjects: 30
Study: 3886394

Group type: EXPERIMENTAL
Intervention: Binedaline 100 mg (females) and 150 mg (males)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline 50 mg and 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binedaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binedaline and Amitriptyline
Number of subjects: 0
Study: 29457317

Group type: EXPERIMENTAL
Intervention: Alcohol infusion (0.08% blood alcohol level)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 54
Study: 29692566

Group type: EXPERIMENTAL
Intervention: Immediate loading protocol (Group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional loading protocol (Group II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of immediate loading to delayed loading protocol
Number of subjects: 20
Study: 27416664

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg qd
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (Tamsulosin 20 mg qd)
Number of subjects: 116
Study: 23606682

Group type: EXPERIMENTAL
Intervention: COBRA therapy (prednisolone 60 mg/day, tapered to 7.5 mg/day in 6 weeks, methotrexate 7.5 mg/week, sulfasalazine 2 g/day)
Number of subjects: 164

Group type: COMPARATOR
Intervention: COBRA-light therapy (lower dose prednisolone starting at 30 mg/day, tapered to 7.5 mg/day in 9 weeks, methotrexate escalated to 25 mg/week in 9 weeks)
Number of subjects: 164
Study: 21896540

Group type: EXPERIMENTAL
Intervention: GEM + ET (gemcitabine plus cationic liposomal paclitaxel)
Number of subjects: 200

Group type: COMPARATOR
Intervention: GEM (gemcitabine alone)
Number of subjects: 200
Study: 19399887

Group type: EXPERIMENTAL
Intervention: Plasmid VEGF
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17467137

Group type: EXPERIMENTAL
Intervention: Futurabond NR self-etch adhesive with acid etching of the enamel margin
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Futurabond NR self-etch adhesive with acid etching of the whole cavity for 20s
Number of subjects: 183

Group type: COMPARATOR
Intervention: Futurabond NR self-etch adhesive without acid etching (control)
Number of subjects: 183
Study: 16049639

Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine (0.5 g x kg(‐1) x day(‐1) of undiluted alanyl‐glutamine (20%))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study: 12456429

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane and Desflurane
Number of subjects: 40
Study: 10083992

Group type: EXPERIMENTAL
Intervention: Skin puncture (SP) technique
Number of subjects: 82

Group type: COMPARATOR
Intervention: No skin puncture (NP) technique
Number of subjects: 82
Study: 7728369

Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Biperiden (4 mg/day)
Number of subjects: 26
Study: 1674835

Group type: EXPERIMENTAL
Intervention: Active TENS during treatment and active TENS during stress
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Active TENS during treatment and placebo TENS during stress
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo TENS during treatment and placebo TENS during stress
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Placebo TENS during treatment and active TENS during stress
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment during both treatment and stress
Number of subjects: 90
Study: 6110504

Group type: EXPERIMENTAL
Intervention: Indenolol 40, 80, 160, and 320 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol 40, 80, 160, and 320 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6734921

Group type: EXPERIMENTAL
Intervention: Buflomedil 600 mg/day orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30012120

Group type: EXPERIMENTAL
Intervention: Environmental level diet and physical activity intervention targeting obesity
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (comparison sites)
Number of subjects: 10
Study: 27555505

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Higher weekly alcohol consumption
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) among sexually active participants
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Higher depressive symptoms (PHQ-9)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Increased number of physical comorbidities
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Diuretic use in participants with chronic kidney disease
Number of subjects: 635
Study: 23868103

Group type: EXPERIMENTAL
Intervention: Helplessness/hopelessness
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: Physical workload
Number of subjects: 1746

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 1746
Study: 22314457

Group type: EXPERIMENTAL
Intervention: Jet nebulizer
Number of subjects: 50

Group type: COMPARATOR
Intervention: MDI with home-made non-valved spacer (HM NVS)
Number of subjects: 50
Study: 20351369

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 100
Study: 18707117

Group type: EXPERIMENTAL
Intervention: 10 g of collagen hydrolysate (CH) in 100 mL of fermented milk product (FMP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 10 g of collagen hydrolysate (CH) dissolved in 100 mL of water (neat hydrolyzed collagen)
Number of subjects: 15
Study: 16135577

Group type: EXPERIMENTAL
Intervention: Advance provision of 3 packs of Plan B
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clinic access (control)
Number of subjects: 90
Study: 11570641

Group type: EXPERIMENTAL
Intervention: Anti-IL-6 monoclonal antibody (1 microg/ml)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Anti-IL-10 monoclonal antibody (1 microg/ml)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined anti-IL-6 and anti-IL-10 monoclonal antibodies (each at 1 microg/ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal pooled O+ sera
Number of subjects: 50
Study: 9559446

Group type: EXPERIMENTAL
Intervention: 8-week cardiac rehabilitation intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 201
Study: 8163319

Group type: EXPERIMENTAL
Intervention: Moderate exercise training on a cycle ergometer 3 times a week for 45 min at 75% VO2max
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sedentary lifestyle (6 weeks)
Number of subjects: 19
Study: 3277388

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 29748315

Group type: EXPERIMENTAL
Intervention: Circulating PCSK9 levels associated with genetic variants (lead SNP rs11591147, PCSK9-R46L)
Number of subjects: 3290

Group type: EXPERIMENTAL
Intervention: Circulating PCSK9 levels
Number of subjects: 3290

Group type: EXPERIMENTAL
Intervention: PCSK9 gene locus variants
Number of subjects: 3290

Group type: EXPERIMENTAL
Intervention: Mendelian Randomization (MR) analysis
Number of subjects: 3290
Study: 27151969

Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI) - up to six counselling sessions offered
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control (usual management including advice on alternative services)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI)
Number of subjects: 267
Study: 24565750

Group type: EXPERIMENTAL
Intervention: 0.15mmol/kg contrast agent
Number of subjects: 31
Study: 22378583

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Non-treatment control
Number of subjects: 125
Study: 20798988

Group type: EXPERIMENTAL
Intervention: Nurse-administered education program (Group 1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Nurse-administered education program with additional pharmacist counseling (Group 2)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (routine care only)
Number of subjects: 91
Study: 18043787

Group type: EXPERIMENTAL
Intervention: Case conferences
Number of subjects: 461

Group type: COMPARATOR
Intervention: Routine care by SPCS
Number of subjects: 461
Study: 16275525

Group type: EXPERIMENTAL
Intervention: Coronary flow velocity (CFV) measured at day 1 after reperfusion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Coronary flow velocity (CFV) measured immediately after reperfusion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Poor wall-motion recovery group (1-month AWMSI > 2.0, n = 14) CFV at day 1
Number of subjects: 29
Study: 12040546

Group type: EXPERIMENTAL
Intervention: Scenario 1 (patient in coma, not going to survive ICU)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Scenario 2 (patient lapsing in and out of consciousness)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Awareness of life support withdrawal
Number of subjects: 128
Study: 9585279

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupivacaine (7.5 mg) without epinephrine
Number of subjects: 12
Study: 7642863

Group type: EXPERIMENTAL
Intervention: Palmaz-Schatz stent implantation
Number of subjects: 589

Group type: COMPARATOR
Intervention: Historical balloon angioplasty control series
Number of subjects: 589
Study: 2757828

Group type: EXPERIMENTAL
Intervention: tinted lenses
Number of subjects: 24
Study: 790410

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0